Toxoplasma gondii is an intracellular protozoan parasite that can infect a wide range of warm-blooded animals. Humans as an intermediate host are infected by ingesting infectious oocytes or tissue cysts, or passing through the placenta in pregnant women. The aim of this study is producing monoclonal antibodies against a synthetic peptide from (surface antigen 1 [SAG1] or P30) protein of T. gondii. A synthetic peptide from SAG1 (P30) protein was conjugated to Keyhole Limpet Hemocyanin (KLH (and then used for immunization of two BALB/c mice. The produced antibody was purified by affinity chromatography and its specific interaction with the immunized peptide was then determined by enzyme-linked immunosorbent assay (ELISA). Immunoreactivity of the antibody was also tested by Western blot in T. gondii cell lysate. The results show that the produced antibody has excellent reactivity with the immunizing peptide and also detects a single band of 30 kDa, which corresponds to SAG1 protein. This antibody can be used as a tool in different applications in T. gondii research areas, including diagnosis, therapy, and infection inhibition.
Get full access to this article
View all access options for this article.
References
1.
DenkersEY, and GazzinelliRT: Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev, 1998; 11:569–588.
2.
JoinerKA, and RoosDS: Secretory traffic in the eukaryotic parasite Toxoplasma gondii: Less is more. J Cell Biol, 2002; 157:557–563.
3.
FrenkelJ, DubeyJ, and MillerNL: Toxoplasma gondii in cats: Fecal stages identified as coccidian oocysts. Science, 1970; 167:893–896.
4.
TenterAM: Toxoplasma gondii in animals used for human consumption. Mem Inst Oswaldo Cruz, 2009; 104:364–369.
5.
CarruthersVB, and SuzukiY: Effects of Toxoplasma gondii infection on the brain. Schizophr Bull, 2007; 33:745–751.
6.
TenterAM, HeckerothAR, and WeissLM: Toxoplasma gondii: From animals to humans. Int J Parasitol, 2000; 30:1217–1258.
7.
BojarI, and SzymanskaJ: Environmental exposure of pregnant women to infection with Toxoplasma gondii-state of the art. Ann Agric Environ Med, 2010; 17:209–214.
8.
LuftBJ, and RemingtonJS: Toxoplasmic encephalitis in AIDS. Clin Infect Dis, 1992; 15:211–222.
9.
WallonM, KodjikianL, BinquetC, GarwegJ, FleuryJ, QuantinC, and PeyronF: Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics, 2004; 113:1567–1572.
10.
BladerIJ, and SaeijJP: Communication between Toxoplasma gondii and its host: Impact on parasite growth, development, immune evasion, and virulence. APMIS, 2009; 117:458–476.
11.
CouvreurG, SadakA, FortierB, and DubremetzJ: Surface antigens of Toxoplasma gondii. Parasitology, 1988; 97:1–10.
12.
Velge-RousselF, ChardesT, MévélecP, BrillardM, HoebekeJ, and BoutD: Epitopic analysis of the Toxoplasma gondii major surface antigen SAG1. Mol Biochem Parasitol, 1994; 66:31–38.
13.
GrimwoodJ, MineoJR, and KasperLH: Attachment of Toxoplasma gondii to host cells is host cell cycle dependent. Infect Immun, 1996; 64:4099–4104.
14.
KasperL, and MineoJ: Attachment and invasion of host cells by Toxoplasma gondii. Parasitol Today, 1994; 10:184–188.
15.
RobinsonS, SmithJ, and MillnerP: Toxoplasma gondii major surface antigen (SAG1): In vitro analysis of host cell binding. Parasitology, 2004; 128:391–396.
16.
NielsenHV, LauemøllerSL, ChristiansenL, BuusS, FomsgaardA, and PetersenE: Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding theSAG1 gene. Infect Immun, 1999; 67:6358–6363.
17.
PetersenE, NielsenHV, ChristiansenL, and SpenterJ: Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine, 1998; 16:1283–1289.
18.
YangC-D, ChangG-N, and ChaoD: Protective immunity against Toxoplasma gondii in mice induced by a chimeric protein rSAG1/2. Parasitol Res, 2004; 92:58–64.
19.
KöhlerG, and MilsteinC: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975; 256:495.
20.
ShojaeianS, AllamehA, ZarnaniAH, ChamankhahM, GhodsR, BayatAA, and Jeddi-TehraniM: Production and characterization of monoclonal antibodies against the extracellular domain of CA 125. Immunol Invest, 2010; 39:114–131.
21.
HadaviR, ZarnaniAH, AhmadvandN, MahmoudiAR, BayatAA, MahmoudianJ, SadeghiM-R, SoltanghoraeeH, AkhondiMM, TarahomiM, Jeddi-TehraniM, and RabbaniH: Production of monoclonal antibody against human nestin. Avicenna J Med Biotechnol, 2010; 2:69.
22.
YousefiM, TahmasebiF, YounesiV, RazaviA, KhoshnoodiJ, BayatAA, AbbasiE, RabbaniH, Jeddi-TehraniM, and ShokriF: Characterization of neutralizing monoclonal antibodies directed against tetanus toxin fragment C. J Immunotoxicol, 2014; 11:28–34.
23.
ZareiS, BayatAA, HadaviR, MahmoudiAR, TavangarB, VojganiY, Jeddi-TehraniM, and AmirghofranZ: Production and characterization of a peptide-based monoclonal antibody against CD44 variant 6. Monoclon Antib Immunodiagn Immunother, 2015; 34:36–43.
24.
MontoyaJG: Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis, 2002; 185(Supplement_1):S73–S82.
25.
NissapatornV, LeeC, QuekKF, LeongCL, MahmudR, and AbdullahKA: Toxoplasmosis in HIV/AIDS patients: A current situation. Jpn J Infect Dis, 2004; 57:160–165.
26.
RemingtonJS, and KleinJO: Infectious Diseases of the Fetus and Newborn Infant. California: WB Saunders, 2001.
27.
SinghS: Mother-to-child transmission and diagnosis of Toxoplasma gondii infection during pregnancy. Indian J Med Microbiol, 2003; 21:69.
28.
ChenX-G, FungM-C, MaX, PengH-J, ShenS-M, and LiuG-Z: Baculovirus expression of the major surface antigen of Toxoplasma gondii and the immune response of mice injected with the recombinant P30. Southeast Asian J Trop Med Public Health, 1999; 30:42–46.
29.
HaumontM, DelhayeL, GarciaL, JuradoM, MazzuP, DaminetV, VerlantV, BollenA, BiemansR, and JacquetA: Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model. Infect Immun, 2000; 68:4948–4953.
30.
QuD-F, YuH-J, LiuZ, ZhangD-F, ZhouQ-J, ZhangH-L, and DuA-F: Ginsenoside Rg1 enhances immune response induced by recombinant Toxoplasma gondii SAG1 antigen. Vet Parasitol, 2011; 179:28–34.
31.
AngusCW, Klivington-EvansD, DubeyJP, and KovacsJA: Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis, 2000; 181:317–324.
32.
CouperKN, NielsenHV, PetersenE, RobertsF, RobertsCW, and AlexanderJ: DNA vaccination with the immunodominant tachyzoite surface antigen (SAG-1) protects against adult acquired Toxoplasma gondii infection but does not prevent maternofoetal transmission. Vaccine, 2003; 21:2813–2820.
33.
DarcyF, MaesP, Gras-MasseH, AuriaultC, BossusM, DesleeD, GodardI, CesbronMF, TartarA, and CapronA: Protection of mice and nude rats against toxoplasmosis by a multiple antigenic peptide construction derived from Toxoplasma gondii P30 antigen. J Immunol, 1992; 149:3636–3641.
34.
GodardI, EstaquierJ, ZennerL, BossusM, AuriaultC, DarcyF, Gras-MasseH, and CapronA: Antigenicity and immunogenicity of P30-derived peptides in experimental models of toxoplasmosis. Mol Immunol, 1994; 31:1353–1363.
35.
Cakir-KocR: Production of anti-SAG1 IgY antibody against Toxoplasma gondii parasites and evaluation of antibody activity by ELISA method. Parasitol Res, 2016; 115:2947–2952.
36.
GrimwoodJ, and SmithJE: Toxoplasma gondii: The role of a 30-kDa surface protein in host cell invasion. Exp Parasitol, 1992; 74:106–111.
37.
MineoJR, McLeodR, MackD, SmithJ, KhanIA, ElyKH, and KasperLH: Antibodies to Toxoplasma gondii major surface protein (SAG-1, P30) inhibit infection of host cells and are produced in murine intestine after peroral infection. J Immunol, 1993; 150:3951–3964.
38.
GondimLFP, WolfA, VrhovecMG, PantchevN, BauerC, LangenmayerMC, BohneW, TeifkeJP, DubeyJP, ConrathsFJ, and ScharesG: Characterization of an IgG monoclonal antibody targeted to both tissue cyst and sporocyst walls of Toxoplasma gondii. Exp Parasitol, 2016; 163:46–56.
39.
HafidJ, VincentN, FloriP, BelleteB, RaberinH, and SungRTM: Production of antibodies in murine mucosal immunization with Toxoplasma gondii excreted/secreted antigens. Vet Parasitol, 2005; 128:23–28.
40.
KhanI, SmithK, and KasperL: Induction of antigen-specific parasiticidal cytotoxic T cell splenocytes by a major membrane protein (P30) of Toxoplasma gondii. J Immunol, 1988; 141:3600–3605.
41.
HajissaK, ZakariaR, SuppianR, and MohamedZ: Design and evaluation of a recombinant multi-epitope antigen for serodiagnosis of Toxoplasma gondii infection in humans. Parasit Vectors, 2015; 8:315.
42.
TrierNH, HansenPR, and HouenG: Production and characterization of peptide antibodies. Methods, 2012; 56:136–144.
43.
Letscher-BruV, PfaffAW, Abou-BacarA, FilisettiD, AntoniE, VillardO, KleinJP, and CandolfiE: Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice. Infect Immun, 2003; 71:6615–6619.
44.
PotasmanI, AraujoFG, DesmontsG, and RemingtonJS: Analysis of Toxoplasma gondii antigens recognized by human sera obtained before and after acute infection. J Infect Dis, 1986; 154:650–657.
45.
KeshavarzH, and ShojaeeS: Detection of Toxoplasma gondii antigens in sera and urine of experimentally infected mice by capture ELISA. Iran J Parasitol, 2008; 3:1–5.
